NClip

Hematologic Cancers Leukemia Lymphoma and Myeloma

3 min read

Hematologic Cancers Leukemia Lymphoma and Myeloma

Key Points

  • Hematologic cancers disrupt bone-marrow and lymphatic function, causing cytopenia-driven instability.
  • Initial high-yield cues include fatigue and pallor (anemia), bruising or bleeding (thrombocytopenia), and infection risk (neutropenia).
  • Pancytopenia is common in leukemia progression and often worsens during intensive treatment phases.
  • Core therapies include chemotherapy, targeted therapy, immunotherapy, radiation in selected pathways, and stem-cell transplant planning.
  • Nursing care is high-intensity during induction and consolidation phases and depends on continuous monitoring plus supportive transfusion and infection control.

Pathophysiology

Blood cancers alter hematopoietic and immune-cell development in marrow and lymphatic tissues. The disease process impairs normal production and function of red cells, platelets, and white-cell lines, reducing oxygen delivery, hemostatic stability, and host defense.

In leukemia pathways, abnormal immature white-cell proliferation crowds out healthy marrow elements, creating broad cell-line suppression even though the primary disease involves white blood cells.

Classification

  • Leukemia: Malignant proliferation of abnormal immature white cells; major clinical categories include ALL, AML, CLL, and CML.
  • Lymphoma: Lymphatic-system malignancy, with Hodgkin and non-Hodgkin pathways; Reed-Sternberg cells define Hodgkin lymphoma.
  • Lymphoma risk context: Infection-associated patterns include EBV, HIV, selected herpes viruses, and hepatitis C seropositivity; non-Hodgkin lymphoma burden increases in older adults and is more common in males.
  • Myeloma: Plasma-cell malignancy in marrow that weakens normal antibody production and increases infection vulnerability.

Nursing Assessment

NCLEX Focus

Trend multi-lineage decline early and escalate rapidly when infection or bleeding cues appear.

  • Assess for fatigue, pallor, exertional intolerance, dizziness, and other anemia-linked symptoms.
  • Assess for bruising, mucosal bleeding, petechiae, or other thrombocytopenia cues.
  • Assess for fever, recurrent infection, and neutropenia-linked deterioration risk.
  • Trend CBC patterns for anemia, thrombocytopenia, neutropenia, and pancytopenia through each therapy phase.
  • In lymphoma pathways, assess for lymph-node enlargement, fever, and night sweats.
  • Assess treatment tolerance continuously during induction and consolidation windows, especially during prolonged inpatient care.

Nursing Interventions

  • Implement bleeding and infection precautions based on current cell-line counts and trends.
  • Provide frequent reassessment for new fever, bleeding, respiratory compromise, or hemodynamic instability.
  • Coordinate supportive therapies commonly required during intensive treatment, including transfusions, antimicrobial therapy, and electrolyte replacement.
  • Reinforce expected treatment-course burden and safety escalation thresholds for patients and caregivers.
  • Coordinate transition planning when marrow recovery begins and outpatient maintenance or follow-up phases start.

High-Yield Treatment Pattern

  • AML induction example: “7 + 3” pattern (continuous cytarabine for 7 days plus anthracycline for first 3 days) with close inpatient monitoring.
  • Post-induction consolidation: High-dose cytarabine cycles (HiDAC) in selected pathways.
  • Supportive-care core: Blood-product support and growth-factor strategies are commonly needed as counts recover.

Self-Check

  1. Why can leukemia present with pancytopenia even though it starts in white-cell lines?
  2. Which findings require fastest escalation during AML induction therapy?
  3. How do nursing priorities shift from induction to post-treatment count-recovery phases?

Graph View